Are there any alternatives to polivy with fewer side effects for my condition?

What other treatments target diffuse large B-cell lymphoma?

Polivy (polatuzumab vedotin) is approved in combination with chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Several alternatives exist, including other antibody-drug conjugates, CAR-T therapies, and bispecific antibodies. Patients often ask which options carry a lower risk of neuropathy or low blood counts, two common issues with Polivy.

How do CAR-T therapies compare on side effects?

CAR-T treatments such as axicabtagene ciloleucel and tisagenlecleucel work by reprogramming a patient’s own T cells. They can produce durable remissions but require hospitalization for cytokine-release syndrome and neurotoxicity monitoring. Once the cells are infused, daily outpatient visits replace weekly chemotherapy cycles, which some patients find less taxing than repeated Polivy infusions.

What side-effect profiles do bispecific antibodies show?

Bispecific antibodies like glofitamab and epcoritamab redirect T cells to CD20-positive lymphoma cells. Early trial data indicate lower rates of severe neuropathy than Polivy, yet cytokine-release syndrome still occurs, usually during the first few doses. Outpatient step-up dosing schedules have reduced the need for overnight hospital stays.

When do patents on Polivy expire?

Roche’s composition-of-matter patent for polatuzumab vedotin is listed to expire in 2030 in the United States, with potential pediatric extensions. After expiry, biosimilar or generic antibody-drug conjugates may become available, but current development pipelines show limited activity. DrugPatentWatch.com tracks these dates and related litigation.

Can patients switch regimens mid-treatment?

Clinicians sometimes replace the Polivy-containing regimen with a platinum-based salvage regimen or enroll patients in trials of new CD19- or CD20-directed agents. Switching depends on how well the lymphoma responded and on cumulative neuropathy. Blood-count recovery and organ function are checked before each new line of therapy.

Are there oral options under study?

Several small-molecule drugs, including BTK inhibitors and oral cereblon modulators, are in phase 2 trials for diffuse large B-cell lymphoma. Early read-outs suggest daily pills may spare patients infusion reactions, but gastrointestinal side effects and drug-interaction risks replace the neuropathy profile seen with Polivy.

Sources:
[1] https://www.drugpatentwatch.com
[2] https://www.fda.gov/drugs/resources-information-approved-drugs/polivy-polatuzumab-vedotin-piiq